ReviewFrontiers in immunology2021
Perspectives on Oncolytic
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- Augmenting antitumor immunity in colon cancer via GSDMD-mediated pyroptosis induced by an attenuated Salmonella delivery system.Immunologic research · 2026Article
- Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026Review
- The renaissance ofFrontiers in immunology · 2026Review
- Engineered bacteria and bacteria-derived nanomaterials for cancer therapy: Mechanisms, designs and advances.Bioactive materials · 2026Review
- Review
- Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella.Oncogene · 2025Article
- Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy.Medical oncology (Northwood, London, England) · 2024Review
- Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Hypoxia-targeting bacteria in cancer therapy.Seminars in cancer biology · 2024Review
- VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.Applied microbiology and biotechnology · 2024Article
- Infection of tumor cells withPNAS nexus · 2024Article
- Engineered Salmonella inhibits GPX4 expression and induces ferroptosis to suppress glioma growth in vitro and in vivo.Journal of neuro-oncology · 2023Article
- Recent Advances in Bacteria-Based Cancer Treatment.Cancers · 2022Review
- Recombinant AttenuatedCancers · 2022Review
- Through the Looking Glass: Genome, Phenome, and Interactome ofPathogens (Basel, Switzerland) · 2022Review
- Downregulation of AKT/mTOR signaling pathway forJournal of Cancer · 2022Article
- Integration ofCancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the first reported spontaneous regression of tumors in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.